The 20 references in paper Н. Воробьева М., Е. Панченко П., Н. Воробьева М., Е. Панченко П. (2015) “ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ДАБИГАТРАНА У ПОЖИЛЫХ БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ (РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ MEDICARE)” / spz:neicon:aterotromboz:y:2015:i:1:p:31-39

1
Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart, 2001, 86: 516–521.
(check this in PDF content)
2
Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285: 2370–2375.
(check this in PDF content)
3
Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 2006, 114: 119–125.
(check this in PDF content)
4
Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart. J., 2006, 27: 949–953.
(check this in PDF content)
5
Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol., 2009, 104: 1534–1539.
(check this in PDF content)
6
Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation, 2004, 110: 1042–1046.
(check this in PDF content)
7
Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005: CD001927.
(check this in PDF content)
8
Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and metaanalysis. Thromb. Res., 2006, 118: 321–333.
(check this in PDF content)
9
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med., 2007, 146: 857–867.
(check this in PDF content)
10
Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation. A systematic review and meta-analysis. Chest, 2004, 126: 1938–1945.
(check this in PDF content)
11
Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost., 2010, 103: 1116–1127.
(check this in PDF content)
12
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 361: 1139–1151.
(check this in PDF content)
13
Connolly SJ, Wallentin L, Ezekowitz MD et al. The LongTerm Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELYABLE) Study. Circulation, 2013, 128: 237–243.
(check this in PDF content)
14
Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation, published online October 30, 2014; DOI: 10.1161/CIRCULATIONAHA.114.012061.
(check this in PDF content)
15
Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA, 2001, 285: 2864–2870.
(check this in PDF content)
16
Pisters R, Lane DA, Nieuwlaat R et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010, 138: 1093–1100.
(check this in PDF content)
17
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predispostion, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol., 2011, 57: 173–180.
(check this in PDF content)
18
Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N. Engl. J. Med., 2013, 368: 1274–1278.
(check this in PDF content)
19
Sorensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use in Danish atrial fibrillation patients in
(check this in PDF content)
20
1: a nationwide study. BMJ Open, 2013, 3: e002758. 20. Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in «realworld» patients with atrial fibrillation. J. Am. Coll. Cardiol., 2013, 61: 2264–2273.
(check this in PDF content)